摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-甲基-4-(6-甲基-2-吡啶基)哌嗪 | 127158-81-0

中文名称
1-甲基-4-(6-甲基-2-吡啶基)哌嗪
中文别名
8-溴甲基萤蒽
英文名称
6-methyl-2-[1-(4-methylpiperazinyl)]pyridine
英文别名
1-Methyl-4-(6-methylpyridin-2-yl)piperazine
1-甲基-4-(6-甲基-2-吡啶基)哌嗪化学式
CAS
127158-81-0
化学式
C11H17N3
mdl
——
分子量
191.276
InChiKey
VYZPEWUEPPGXGA-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    312.9±42.0 °C(Predicted)
  • 密度:
    1.049±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.5
  • 重原子数:
    14
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.55
  • 拓扑面积:
    19.4
  • 氢给体数:
    0
  • 氢受体数:
    3

SDS

SDS:29c86b3f72854ec24f201524db4ee267
查看

反应信息

  • 作为产物:
    描述:
    参考文献:
    名称:
    Structure−Activity Relationships for the Binding of Arylpiperazines and Arylbiguanides at 5-HT3 Serotonin Receptors
    摘要:
    Arylpiperazines are nonselective agents that bind at 5-HT3 serotonin receptors with moderate to high affinity, whereas 1-phenylbiguanide is a low-affinity but more selective 5-HT3 agonist. In an attempt to enhance the affinity of the latter agent, and working with the assumption that similarities might exist between the binding of the two types of agents, we formulated structure-activity relationships for the binding of the arylpiperazines and then incorporated those substituents, leading to high affinity for the arylpiperazines, into 1-phenylbiguanide. A subsequent investigation examined the structure-activity relationships of the arylbiguanides and identified arylguanidines as a novel class of 5-HT3 ligands. Although curious similarities exist between the structure-activity relationships of the arylpiperazines, arylbiguanides, and arylguanidines, it cannot be concluded that all three series of compounds are binding in the same manner. Furthermore, upon investigating pairs of compounds in the three series, the arylpiperazines behaved as 5-HT3 antagonists (von Bezold-Jarisch assay) whereas the arylbiguanides and arylguanidines acted as 5-HT3 agonists.
    DOI:
    10.1021/jm9603936
点击查看最新优质反应信息

文献信息

  • [EN] 2-PYRIDYL CARBOXAMIDE-CONTAINING SPLEEN TYROSINE KINASE (SYK) INHIBITORS<br/>[FR] INHIBITEURS DE TYROSINE KINASE DE LA RATE (SYK) CONTENANT UN 2-PYRIDYL CARBOXAMIDE
    申请人:MERCK SHARP & DOHME
    公开号:WO2013052394A1
    公开(公告)日:2013-04-11
    The invention provides certain 2-pyridyl carboxamide-containing compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein A and B are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated by Spleen Tyrosine Kinase (Syk) kinase.
    本发明提供了一些含有2-吡啶甲酰胺的化合物,其化学式为(I)或药用可接受的盐,其中A和B按本发明定义。本发明还提供了包含这些化合物的药物组合物,以及使用这些化合物来治疗由脾酪氨酸激酶(Syk)介导的疾病或状况的方法。
  • Novel Aryl Piperazine Derivatives With Medical Utility
    申请人:Campiani Giuseppe
    公开号:US20090238761A1
    公开(公告)日:2009-09-24
    This invention provides novel aryl piperazine derivatives having medical utility, in particular as modulators of dopamine and serotonin receptors, preferably the D 3 , D 2 -like and 5-HT 2 receptor subtypes, and in particular useful for the treatment of neuropsychiatric disorders incl. schizophrenia.
    这项发明提供了具有医疗效用的新型芳基哌嗪衍生物,特别是作为多巴胺和5-羟色胺受体的调节剂,优选为D3、D2样和5-HT2受体亚型,特别适用于治疗包括精神分裂症在内的神经精神障碍。
  • SUBSTITUTED 6-AMINO-NICOTINAMIDES AS KCNQ2/3 MODULATORS
    申请人:Kühnert Sven
    公开号:US20120101079A1
    公开(公告)日:2012-04-26
    Substituted 6-amino-nicotinamides, pharmaceutical compositions containing these compounds and also use of these compounds in the treatment and/or prophylaxis of pain and further diseases and/or disorders.
    6-氨基烟酰胺,含有这些化合物的药物组合物,以及这些化合物在治疗和/或预防疼痛以及其他疾病和/或紊乱中的用途。
  • [EN] SUBSTITUTED 6-AMINO-NICOTINAMIDES AS KCNQ2/3 MODULATORS<br/>[FR] 6-AMINO-NICOTINAMIDES SUBSTITUÉS EN TANT QUE MODULATEURS DES KCNQ2/3
    申请人:GRUENENTHAL GMBH
    公开号:WO2012052167A1
    公开(公告)日:2012-04-26
    The invention relates to substituted 6 -amino-nicotinamides of general formula (I) to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.
    这项发明涉及通式(I)的取代6-氨基烟酰胺衍生物,以及含有这些化合物的药物组合物,还涉及这些化合物在治疗和/或预防疼痛以及其他疾病和/或紊乱方面的用途。
  • 8-OXODIHYDROPURINE DERIVATIVE
    申请人:Aachi Keiji
    公开号:US20120172347A1
    公开(公告)日:2012-07-05
    The present invention provides a compound represented by the formula (1) or a pharmaceutically acceptable salt thereof (wherein W represents a hydrogen atom, a halogen atom, or the others; A represents an alkyl group optionally substituted by aryl group or the others, an aryl group, or the others; and one of X and Y represents a di-substituted alkylaminocarbonyl group, or the others, and the other represents a hydrogen atom, an alkyl group, an alkylcarbonyl group, or the others); a medicament or a pharmaceutical composition for treatment or prophylaxis of FAAH-related diseases such as depression, anxiety disorder or pains, comprising the compound or the like as an active ingredient; a use of the compound or the like; and a method for treatment or prophylaxis using the compound or the like.
    本发明提供一种由式(1)表示的化合物或其药用可接受的盐(其中W代表氢原子、卤素原子或其他;A代表可选地被芳基取代的烷基基团或其他、芳基团或其他;X和Y中的一个代表二取代的烷基氨基羰基团或其他,另一个代表氢原子、烷基基团、烷基羰基团或其他);一种治疗或预防FAAH相关疾病如抑郁症、焦虑症或疼痛的药物或药物组合物,包括该化合物或类似物作为活性成分;一种使用该化合物或类似物的用途;以及使用该化合物或类似物的治疗或预防方法。
查看更多